Placebo News and Research

RSS

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

19 Mar 2013

Migraine severity may be predicted by blood levels of fat cell hormone

In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.

18 Mar 2013

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

R-Tech Ueno is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa.

18 Mar 2013

Researchers identifiy elusive anti-cancer property of vitamin E

Researchers have identified an elusive anti-cancer property of vitamin E that has long been presumed to exist, but difficult to find. Many animal studies have suggested that vitamin E could prevent cancer, but human clinical trials following up on those findings have not shown the same benefits.

16 Mar 2013

Elevation of stress steroids in the brain speeds up Alzheimer disease

Why does chronic stress lead to increased risk for dementia? The answer may lie in the elevation of stress steroids that is seen in the brain during stress, Sara K. Bengtsson suggests in the thesis she is defending at Umeå University in Sweden on March 22nd.

16 Mar 2013

Interventional endovascular therapy is safe but does not improve MS outcomes: Study

The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation treatment," which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse.

16 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Researchers show inhibiting brain's filter can boost performance for tasks

The brain's prefrontal cortex is thought to be the seat of cognitive control, working as a kind of filter that keeps irrelevant thoughts, perceptions and memories from interfering with a task at hand.

15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Researchers show vitamin D supplementation may help African-Americans lower blood pressure

High blood pressure, a risk factor for heart attacks, heart failure and stroke, is 40 percent more common in African-Americans than in other American ethnic groups.

14 Mar 2013

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Research findings could lead to new sleep therapies to improve memory disorders

A team of sleep researchers led by UC Riverside psychologist Sara C. Mednick has confirmed the mechanism that enables the brain to consolidate memory and found that a commonly prescribed sleep aid enhances the process.

13 Mar 2013

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013

Placebo News and Research

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

Migraine severity may be predicted by blood levels of fat cell hormone

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

Researchers identifiy elusive anti-cancer property of vitamin E

Elevation of stress steroids in the brain speeds up Alzheimer disease

Interventional endovascular therapy is safe but does not improve MS outcomes: Study

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

Promising studies for Parkinson's to be presented at 65th AAN meeting

Researchers show inhibiting brain's filter can boost performance for tasks

Results from GTx's Phase 2 clinical trial of enobosarm published online

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Researchers show vitamin D supplementation may help African-Americans lower blood pressure

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

Research findings could lead to new sleep therapies to improve memory disorders

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News